🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) ...
Status
Terminated
Location
Highlands Oncology Group
Start Date
2022-12-14
Trial ID
NCT05493501
To assess the efficacy and safety of Almonertinib versus platinum-based che...
Status
Unknown
Location
Sun yat-sen Univerisity Cancer Center
Start Date
2021-07-15
Trial ID
NCT04951648
Treatments Being Tested
Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI ...
Status
Withdrawn
Location
Sun Yat-sen University Cancer Center
Start Date
2024-06-01
Trial ID
NCT06227897
Treatments Being Tested
This is a prospective, open-label, multi-center, single-arm clinical trial...
Status
Unknown
Location
Cancer Hospital Affiliated to University of Chinese Academy of Sciences
Start Date
2021-07-09
Trial ID
NCT04808752
Treatments Being Tested
To assess the efficacy and safety of Almonertinib versus placebo following ...
Status
Recruiting
Location
Shandong Cancer Hospital
Start Date
2021-03-18
Trial ID
NCT04951635
Treatments Being Tested
A Phase II, open label, non-randomized, multiple-arm, single-center clinica...
Status
Recruiting
Location
Cancer hospital Chinese Academy of Medical Sciences
Start Date
2020-08-15
Trial ID
NCT04423185
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus ...
Status
Active Not Recruiting
Location
Shanghai Chest Hospital
Start Date
2021-08-11
Trial ID
NCT04923906
Treatments Being Tested
This is a phase II, single-arm, open-label study to evaluate the efficacy a...
Status
Active Not Recruiting
Location
Shanghai Pulmonary Hospital
Start Date
2021-12-14
Trial ID
NCT04685070
Treatments Being Tested
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific ...
Status
Recruiting
Location
Tianjin Medical University Cancer Institute and Hospital
Start Date
2024-05-28
Trial ID
NCT06417008
Treatments Being Tested
Participants aged 18 to 75 years with severe hepatic impairment (Child-Pugh...
Status
Completed
Location
American Institute Research
Start Date
2022-03-30
Trial ID
NCT05199610
Treatments Being Tested